Green Tea Epigallo-Catechin-Galleate Ameliorates the Development of Obliterative Airway Disease

Experimental Lung Research

Volumn 37, Issue 7, 2011, Pages 435-444

  Liang, Olin D ^a   Kleibrink, Bjoern E ^a,b   Schuette Nuetgen, Katharina ^a,c   Khatwa, Umakanth U ^a   Mfarrej, Bechara ^a   Subramaniam, Meera ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cytokine; Heterotopic tracheal allograft; Neutrophil; Obliterative airway disease

Indexed keywords

EPIGALLOCATECHIN GALLATE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; KERATINOCYTE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REGENERATION; TRACHEA;

ANIMALS; BRONCHIOLITIS OBLITERANS; CATECHIN; CYTOKINES; FIBROSIS; INFLAMMATION; LUNG TRANSPLANTATION; MICE; NEUTROPHIL INFILTRATION; TEA;

EID: 80051760017     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2011.584359     Document Type: Article

References (54)

1. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, Taylor DO, Kucheryavaya AY, Hertz MI: Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant. 2008;27:957-969.
2. Boehler A, Estenne M: Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007-1018.
3. Jaramillo A, et al.: Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant. 2005;9:84-93.
4. Miura, M, El-Sawy T, Fairchild RL: Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma. Am J Pathol. 2003;162:509-519.
5. DiGiovine B, Lynch JP, 3rd, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, Arenberg DA, Burdick MD, Glass MC, Wilke CA, et al.: Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: Role of IL-8. J Immunol. 1996;157:4194-4202.
6. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ: Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J. 1998;12:82-88.
7. Elssner A, Jaumann F, Dobrnann S, Behr J, Schwaiblmair M, Reichenspurner H, Furst H, Briegel J, Vogelmeier C: Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: Proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation. 2000;70:362-367.
8. McDyer JF: Human and murine obliterative bronchiolitis in transplant. Proc Am Thorac Soc. 2007;4:37-43.
9. Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggar R, et al.: Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest. 2005;115:1150-1162.
10. Belperio JA, Keane MP, Burdick MD, Lynch JP, 3rd, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM: Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108:547-556.
11. Belperio JA, Burdick MD, Keane MP, Xue YY, Lynch JP, 3rd, Daugherty BL, Kunkel SL, Strieter RM: The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol. 2000;165:461-472.
12. Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524-529.
13. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J:Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-beta signaling through Smad3-dependent and -independent pathways. Am J Transplant. 2006;6:2080-2088.
14. Frei B, Higdon JV: Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J Nutr. 2003;133:3275S-3284S.
15. Meng M, Li YQ, Yan MX, Kou Y, Ren HB: Effects of epigallocatechin gallate on diethyldithiocarbamate-induced pancreatic fibrosis in rats. Biol Pharm Bull. 2007;30:1091-1096.
16. Kim HR, Park BK, Oh YM, Lee YS, Lee DS, Kim HK, Kim JY, Shim TS, Lee SD: Green tea extract inhibits paraquat-induced pulmonary fibrosis by suppression of oxidative stress and endothelin-l expression. Lung. 2006;184:287-295.
17. March TH, Wilder JA, Esparza DC, Cossey PY, Blair LF, Herrera LK, McDonald JD, Campen MJ, Mauderly JL, Seagrave J: Modulators of cigarette smoke-induced pulmonary emphysema in A/J mice. Toxicol Sci. 2006;92:545-559.
18. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ: Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol. 1993;142:1945-1951.
19. Woessner JF Jr: The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;93:440-447.
20. Klebanoff SJ: Myeloperoxidase: Friend and foe. J Leukoc Biol. 2005;77:598-625.
21. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M: Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010;24:788-798.
22. Borthwick DW, Shahbazian M, Krantz QT, Dorin JR, Randell SH: Evidence for stem-cell niches in the tracheal epithelium. Am J Respir Cell Mol Biol. 2001;24:662-670.
23. Trulock EP: Lung transplantation. Am J Respir Crit CareMed. 1997;155:789-818.
24. Belperio JA, Weigt SS, Fishbein MC, Lynch JP, 3rd: Chronic lung allograft rejection: Mechanisms and therapy. Proc AmThorac Soc. 2009;6:108-121.
25. Hele DJ, Yacoub MH, Belvisi MG: The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis. Respir Res. 2001;2:169-183.
26. Sato M, Keshavjee S, Liu M: Translational research: Animal models of obliterative bronchiolitis after lung transplantation. Am J Transplant. 2009;9:1981-1987.
27. Krupnick AS, Lin X, Li W, Okazaki M, Lai J, Sugimoto S, Richardson SB, Kornfeld CG, Garbow JR, Patterson GA, et al.: Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology. Nat Protocol. 2009;4:86-93.
28. OkazakiM, Gelman AE, Tietjens JR, Ibricevic A, Kornfeld CG, Huang HJ, Richardson SB, Lai J, Garbow JR, Patterson GA, et al.: Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol. 2007;37:625-630.
29. Okazaki M, Krupnick AS, Kornfeld CG, Lai JM, Ritter JH, Richardson SB, Huang HJ, Das NA, Patterson GA, Gelman AE, et al.: A mouse model of orthotopic vascularized aerated lung transplantation. Am J Transplant. 2007;7:1672-1679.
30. Yang CS, Maliakal P, Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002;42:25-54.
31. Na HK, Surh YJ: Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol Nutr Food Res. 2006;50:152-159.
32. Abboud PA, Hake PW, Burroughs TJ, Odoms K, O'Connor M, Mangeshkar P, Wong HR, Zingarelli B: Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol. 2008;579:411-417.
33. Shilling RA, Wilkes DS: Immunobiology of chronic lung allograft dysfunction: New insights from the bench and beyond. Am J Transplant. 2009;9:1714-1718.
34. Grossman EJ, Shilling RA: Bronchiolitis obliterans in lung transplantation: The good, the bad, and the future. Transl Res. 2009;153:153-165.
35. Sumpter TL, Wilkes DS: Role of autoimmunity in organ allograft rejection: A focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1129-L1139.
36. Fukarni N, Ramachandran S, Saini D, WalterM, Chapman W, Patterson GA, Mohanakumar T: Antibodies to MHC class I induce autoimmunity: Role in the pathogenesis of chronic rejection. J Immunol. 2009;182:309-318.
37. Gorbacheva V, Fan R, Li X, Valujskikh A: Interleukin- 17 promotes early allograft inflammation. Am J Pathol. 2010;177:1265-1273.
38. Goo HC, Hwang YS, Choi YR, Cho HN, Suh H: Development of collagenase-resistant collagen and its interaction with adult human dermal fibroblasts. Biomaterials. 2003;24:5099-5113.
39. Khatwa UA, Kleibrink BE, Shapiro SD, Subramaniam M: MMP-8 promotes polymorphonuclear cell migration through collagen barriers in obliterative bronchiolitis. J Leukoc Biol. 2010;87:69-77.
40. Martinu T, Chen DF, Palmer SM: Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc. 2009;6:54-65.
41. Wu D, Guo Z, Ren Z, Guo W, Meydani SN: Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med. 2009;47:636-643.
42. Pae M, Ren Z, Meydani M, Shang F, Meydani SN, Wu D: Epigallocatechin-3- gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression. J Nutr. 2010;140:1509-1515.
43. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246-257.
44. Frangogiannis NG: Chemokines in the ischemic myocardium: From inflammation to fibrosis. Inflamm Res. 2004;53:585-595.
45. Weiss CH, Budinger GR, Mutlu GM, Jain M: Proteasomal regulation of pulmonary fibrosis. Proc Am Thorac Soc. 2010;7:77-83.
46. Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q: Role of TGF-{beta} in airway remodeling in asthma. Am J Respir Cell Mol Biol. 2011;44:127-133.
47. Krebs R, Tikkanen JM, Nykanen AI, Wood J, Jeltsch M, Yla- Herttuala S, Koskinen PK, Lemstrom KB: Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Respir Crit Care Med. 2005;171:1421-1429.
48. Krebs R, Hollmen ME, Tikkanen JM, Wu Y, Hicklin DJ, Koskinen PK, Lemstrom KB: Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. Transplant Proc. 2006;38:3266-3267.
49. Tikkanen JM, HollmenM, Nykanen AI,Wood J, Koskinen PK, Lemstrom KB: Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med. 2006;174:1145-1152.
50. Douglas IS, Nicolls MR: Chemokine-mediated angiogenesis: An essential link in the evolution of airway fibrosis? J Clin Invest. 2005;115:1133-1136.
51. Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789-791.
52. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995;182:155-162.
53. Keane MP, Arenberg DA, Lynch JP, 3rd, Whyte RI, Iannettoni MD, Burdick MD, WilkeCA, Morris SB,Glass MC,DiGiovine B, et al.: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997;159:1437-1443.
54. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, Polosukhin V, Zhao LH, Sakamoto H, Blackwell TS, et al.: Inhibition of pulmonary fibrosis by the chemokine IP- 10/CXCL10. Am J Respir Cell Mol Biol. 2004;31:395-404.